The Minister of Health has stated that the SNS24 line has received “more than 62 thousand calls” since December 26, warning that “the next two weeks.
Following the switch from natalizumab, patients with multiple sclerosis on anti-CD20 therapies like rituximab demonstrated significant reductions in annualized relapse rate.
Patients who are diagnosed with axial spondyloarthritis after referral to a rheumatologist for chronic back pain most often keep that diagnosis, providing good reason to refer patients early.